CROCI, STEFANIA
 Distribuzione geografica
Continente #
NA - Nord America 357
EU - Europa 321
AS - Asia 65
Totale 743
Nazione #
US - Stati Uniti d'America 356
GB - Regno Unito 165
IE - Irlanda 62
CN - Cina 32
UA - Ucraina 25
SE - Svezia 20
VN - Vietnam 18
IT - Italia 14
FR - Francia 12
TR - Turchia 8
FI - Finlandia 6
DE - Germania 4
ES - Italia 4
IN - India 3
RU - Federazione Russa 3
AT - Austria 2
BE - Belgio 2
SG - Singapore 2
BD - Bangladesh 1
CA - Canada 1
IR - Iran 1
LT - Lituania 1
PL - Polonia 1
Totale 743
Città #
Southend 157
Dublin 59
Fairfield 56
Chandler 39
Ashburn 34
Seattle 24
Menlo Park 23
Wilmington 20
Woodbridge 20
Jacksonville 19
Dong Ket 18
Cambridge 17
Ann Arbor 16
Beijing 10
Houston 10
Dearborn 9
Izmir 8
New York 8
Princeton 8
Siena 8
Helsinki 6
Fremont 5
Munich 4
Málaga 4
Shanghai 4
Shenyang 4
Boardman 3
Hebei 3
Phoenix 3
San Diego 3
Brussels 2
Florence 2
Jinan 2
Moscow 2
Nanchang 2
San Mateo 2
Sezze 2
Tianjin 2
Vienna 2
Bangalore 1
Dhaka 1
Edinburgh 1
Fuzhou 1
Hangzhou 1
Hounslow 1
Kilburn 1
Kunming 1
Kyiv 1
London 1
Philadelphia 1
Saint Louis 1
San Francisco 1
Sandston 1
Singapore 1
Taizhou 1
Warsaw 1
Washington 1
Winnipeg 1
Zanjan 1
Totale 640
Nome #
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients 239
3D bone texture analysis as a potential predictor of radiationinduced insufficiency fractures 200
Immuno-Inflammatory Markers in Advanced NSCLC Patients Undergone Fractioned Cisplatin, Oral Etoposide and Bevacizumab 175
Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). 147
Totale 761
Categoria #
all - tutte 1.927
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.927


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020173 20 3 8 21 14 19 24 20 17 16 4 7
2020/2021128 5 12 0 19 7 16 2 18 10 9 4 26
2021/202277 5 13 5 1 7 1 6 6 6 6 7 14
2022/2023104 4 13 15 17 12 15 1 8 7 6 4 2
2023/202498 1 1 6 4 1 31 47 0 2 0 0 5
2024/20255 5 0 0 0 0 0 0 0 0 0 0 0
Totale 761